Appendix 4E and Annual Report 2026
Released
Released
Announcement PDF
1. Company Details
Name of Entity: Tetratherix Limited
ABN: 72 607 771 077
For the year ended 30 June 2026
Previous Period: For the year ended 30 June 2025
2. Results for Announcement to the Market
$
Total Revenue and Other Income from Ordinary Activities Up +308% 4,657,553
Underlying Loss for the Year Up +105% (9,320,535)
Loss from Ordinary Activities After Tax Attributable of Tetratherix
Limited
Down -1% (9,320,535)
Loss for the Year Attributable to the Owners of Tetratherix Limited Down -1% (9,320,535)
Dividends
There were no dividends paid, recommended or declared during the current or previous financial period.
Comments
The loss for the Consolidated Entity after providing for income tax amounted to $9,320,535 (30 June 2025 :
$9,425,552).
Underlying loss represents statutory loss for the year adjusted for non-recurring non-operating items.
Refer to the Financial Overview section of the 2026 Annual Report for further information, including a
reconciliation between net loss before tax and underlying loss for the year.
3. Net Tangible Assets
Reporting
Period
Cents
Previous
Period
Cents
Net Tangible Assets per Ordinary
Security
59.52 54.05
4. Control Gained Over Entities
not applicable
5. Loss of Control Over Entities
not applicable
ANNUAL REPORT APPENDIX 4E
1
1
20 AUGUST 2026
PRELIMINARY FINAL REPORT
AS AT 30 JUNE 2026
Tetratherix Limited 2026 1
6. Dividends
Current Period
There were no dividends paid, recommended or declared during the current financial period.
Previous Period
There were no dividends paid, recommended or declared during the previous financial period.
7. Details of Associates and Joint Venture Entities
Reporting Entity’s
Percentage Holding
Name of Associate/Joint Venture
Reporting
Period
%
Previous
Period
%
Tutelix Pty Ltd 38.9% 50.0%
8. Audit Qualification or Review
Details of Audit/Review Dispute or Qualification (if any):
The financial statements have been audited and an unmodified opinion has been issued.
9. Attachments
Details of Attachments (if any):
The Annual Report of Tetratherix Limited for the year ended 30 June 2026 is attached.
10. Signed
William Knox
Executive Director and
CEO
Sydney
Date: 20 August 2026
ANNUAL REPORT APPENDIX 4E
PRELIMINARY FINAL REPORT
AS AT 30 JUNE 2026
Tetratherix Limited 2026 2
Annual Report 2026
Tetratherix Limited
ACN 607 771 077
ASX:TTX Tetratherix Limited 2026
1
About this
Annual Report
This report covers Tetratherix's* operations, activities and financial performance for the year ended 30 June 2026, a milestone year
where our platform matures and that sees our flywheel in full motion.
As always, we do not take our shareholders' investments for granted. We regard ourselves as custodians of that capital, and we run the
Company with the financial hygiene that demands: every dollar is deployed deliberately against milestones we have committed to. That
discipline funded a year of substantive progress - our first full FDA submission for Bone Regeneration, the development of an entirely
new franchise in Precision Medicine, our first licence payment from a commercial partner, and a growing body of clinical trial data that
continues to build strong validation of the Tetramatrix™ platform across indications.
The Tetratherix flywheel is in motion, it is being further boosted by the native incorporation of AI across our developments,
manufacturing and operating systems.
This year we have also produced the report in an agent-ready form. Alongside the designed document, the content has been structured
so that it can be read accurately by AI systems: sections sit under consistent, semantically labelled headings; product, entity and
franchise names follow a single controlled vocabulary; figures carry explicit units, currencies and reporting periods; and tables are
preserved as structured data rather than as images.
Our intention is that investors, analysts and partners using AI tools to interrogate this report receive answers grounded in what we have
actually reported, with fewer transcription errors and less risk of misinterpretation. An AI friendly version of this report is accessible at
https://reports.tetratherix.com/.
This report provides information on matters that we believe could materially affect value creation at Tetratherix. The Board has
collectively identified and prioritised the material issues for inclusion in this report. In this report, we present the identified material
information through a structured narrative.
We review who we are and how we create value through our technology and business model. We report those matters significantly
impacting value and outline our strategy, performance, and outlook to ensure long-term value creation and patient impact. The Board
will continue to engage with key stakeholders and consult with them on matters that interest and impact them and update the market
when necessary. Our ARC verifies the integrity of each periodic report before release, with the Financial Statements and Remuneration
Report independently audited.
References in this report to a ‘year’ or ‘this year’ are to the financial year ended 30 June 2026 (previous corresponding period to 30 June
2025) unless otherwise stated. All years are financial years ending 30 June unless otherwise stated. All dollar figures are Australian dollars
(AUD) unless otherwise stated.
Nexia has conducted an independent audit of the Financial Statements and Remuneration Report. A copy of Nexia’s audit report is
contained in this annual report.
The Tetratherix Investor Hub platform provides existing and prospective shareholders with real‑time access to ASX announcements,
reports and presentations. You can visit the Tetratherix Investor Hub at https://investors.tetratherix.com/.
* references to ‘Tetratherix’, ‘TTX’, ‘the Company’, ‘the Group’, ‘we’, ‘us’ and ‘our’ refer to Tetratherix Limited (ACN 607 771 077 ) and its
subsidiaries, unless otherwise stated.
Annual Report 2026
Tetratherix Limited 2026 2
We are an Australian biomedical technology company, founded in 2015 as an advanced manufacturing and
intellectual property-generating entity in the biomaterial and regenerative medicine space. At our core is our
flagship Tetramatrix™ platform technology.
We commercialise multiple products derived from our Tetramatrix™ platform technology through a flywheel
model in which our established foundational intellectual property, safety, efficacy, and streamlined
manufacturing processes facilitate the rapid and efficient development of products in different fields of
medicine.
We have been building this Company and its platform technology for 15 years, having started the journey as a
PhD thesis at the University of Sydney. The founders and inventors of the technology continue to control and
drive the company towards its mission.
The platform technology allows for multiple parallel commercial opportunities, with the first generation of
products will be launching into global markets in FY27, representing an exciting inflection point in the TTX
journey.
An Introduction to
Tetratherix
Tetramatrix™ is a biostealth fluid technology
engineered to transition at physiological
temperature and form a tissue-adhering 3D matrix
after delivery. Designed as a single platform it can
be adapted to distinct derivatives for different
tissues, indications and delivery requirements
without reinventing the underlying system each
time.
Our Tetramatrix PlatformTechnology
Annual Report 2026
Tetratherix Limited 2026 3
1 2026 in Review 5
2 Our Company 22
3 Directors’ Report 43
4 Auditor’s Independence Declaration 86
5 Financial Report 88
6 Additional Information 147
Table of Contents
Annual Report 2026
Tetratherix Limited 2026 4
Annual Report 2026
Tetratherix Limited 2026
01. 2026 in Review
5
Tetratherix Limited 2026
Dear Shareholders,
It is with great pleasure that I present the Annual Report for Tetratherix Limited for the financial year ended 30 June 2026.
This year has been a period of continued progress and relentless execution. We moved from being a newly listed
company to an organisation delivering on the commercial, clinical, technical and operational goals we set when we listed
on the ASX in June 2025. We achieved significant milestones across our key product areas and continued to strengthen
our organisation to support long-term, sustainable growth.
FY26 was marked by important progress on several fronts. We completed our first full FDA dossiers including
performance and safety testing for our dental and orthopaedic bone regeneration products for initial market launch in
the US. Within Tutelix, our injectable spacer for radiation oncology, we successfully completed the first insertion of the
device into a human patient and progressed to stage 2 of the clinical study, alongside completing an early-stage meeting
with the FDA to discuss our regulatory pathway. TetraDerm, our product for surgical scar reduction, completed its first
patient cohort and progressed through a second, with the third and final cohort set for completion in CY26. We also
introduced our new Precision Medicine franchise and reached a major technical milestone in nasal drug delivery.
Together, these achievements validate our work and will help us accelerate our commercialisation plans across our key
product areas, while we continue to invest in research and development.
We also made considerable progress building long-term partnerships. We finalised our exclusive global quality and supply
agreement with Henry Schein, Inc., one of the world's largest medical distributors, and signed our Superpower Health Inc.
research and development agreement, which secures us a licence payment of US$3 million a year for up to ten years,
along with expected sales of our polymer technology. We signed an exclusive licensing agreement with BioOptix, Inc.,
which has itself partnered with Alcon Research, and our Tutelix joint venture accelerated its major clinical trial program
following its first round of external investment. We also progressed discussions with several potential partners in
orthopaedic bone regeneration for our TegenEOS product. These outcomes reflect the hard work of our entire team and
give us confidence that key stakeholders believe in our mission.
Financially, we directed investment towards research and development, digital systems and production capability,
supported by more than $20 million in additional funding beyond what we originally forecast at IPO. This included a $15.6
million capital raise in May 2026 (before costs), a $3.3 million IGP grant to be received over two years, and $4.2 million in
licence revenue from our Superpower agreement. We ended the year with $34.4 million cash and cash equivalents on
hand and recorded a net loss of $9.3 million. This loss reflects our capital light model, continued investment in research
and development and in our advanced manufacturing capability, offset in part by our first year of licence revenue and
supplemental income from our additional capital raise and IGP grant.
Looking ahead to FY27, our objectives remain clear and our key priorities are:
Secure FDA 510(k) approval for our Bone Regeneration products;
Begin our first commercial production and sales for our Bone Regeneration franchise and STEPP - our nasal drug
delivery product;
Sign a strategic partnership agreement for TegenEOS, our orthopaedic product;
Progress clinical trials for Tutelix, our oncology spacing product, through our joint venture;
Advance pre-clinical trials and complete technical reporting for Optimatrix, our ophthalmic product;
Complete our advanced manufacturing campus and relocate our company headquarters;
Recruit and onboard new team members across our digital, production and customer success teams; and
Commence tracking patient impact following our first product sales.
We would like to thank our entire team for their dedication, without which none of these achievements would be possible.
We also thank our partners and shareholders for their continued support and belief in our vision.
We are excited about the journey ahead and remain committed to finding new possibilities in life sciences. Our mission
remains the same: to use our Tetramatrix™ platform technology to expand healthcare access, improve equity in global
health, and deliver better outcomes and real, positive impact for patients.
Yours sincerely
Emma
Annual Report 2026
Letter From Our Chair
Emma Cleary
Non-Executive Chair
6
FDA 510k
Complete
ISO 13485
Certification
Ralph Street
Lab Built
First Institutional
Funding
IPO
STEPP
Validated
Precision
Medicine Launch
First 50 Patients
Treated
First Global
Partnership
Tetratherix Limited 2026
TTX Timeline - 15 Years in the Making
Fifteen years of deliberate work sit behind
the milestone stack. Every step was
sequenced so it would build on the one
before, carrying us steadily from early
science towards commercial scale. The
structure moves us into commercialisation
and the generational patient impact we set
out to create.
2015 2030
First Patent
Granted
First Clinical
Trial
Impact
Commercialisation
FY2026
Commercial
Launch of the
TTX Platform
WE ARE
HERE
Annual Report 2026
The TTX Decade
Development Arc
7
Platform
Confirmation
Changing the way drugs are delivered
on the back of 5+ years of mRNA
delivery research. Tetratherix has now
launched its drug delivery franchise,
targeting the exciting intersection of
consumer preventative medicine and
metabolic health.
01
Patient impact is how we
measure our success.
Tetramatrix™ platform
technology has now been used
across multiple clinical trials with
over 75 patients included. This
number will significantly grow
upon market clearance in 2026.
58% Growth in
Patient Impact
2026 Highlights
Growing patient impact, anchored by
science. Working closely with our
development partners, TTX has
progressed the clinical safety &
efficacy testing for its pipeline
products in scar prevention, urological
spacing and cataract surgeries.
*The $4.2 million licence revenue is being recognised on a straight-line basis over the 12-month period from April 2026. Of this, $0.9 million has
been recognised in the FY26 P&L, with the remaining $3.3 million to be recognised in FY27.
Tetratherix Limited 2026
Annual Report 2026
02
Reaching the commercial
inflection point. Tetratherix is
now officially a revenue
generating business, having
successfully transitioned from
an R&D house to a commercial
entity.
First Revenues
of $4.2m*
03
Significant regulatory milestone met.
2026 saw TTX complete its first full
FDA dossiers including performance
and safety testing for our dental and
orthopaedic bone regeneration
products for initial market launch in
the US.
Completed First
FDA Submission
04
Federal Government support for
Australian Export. With the support of
a $3.3m IGP grant, we have now
begun the build of our bespoke
advanced manufacturing facility to
increase our capabilities by 10x in
Sydney, Australia with completion
estimated to be in late 2026.
Production
Readiness
Underway
05
Precision
Medicine Launch
06
Paving the Path
with our Pipeline
8
58% Growth in Patient Impact
Patient impact is how we measure our success.
The Tetramatrix™ platform has now been used across multiple clinical trials, with more than 75
patients treated to date, and that number is set to grow considerably once we reach market
clearance in 2026.
Across the year the TetraDerm clinical trial advanced into cohorts 2 and 3, with major wounds now
being treated and with strong indications of performance in reducing scar formation. The Tutelix pilot
trial was completed with 15 patients treated, recording no adverse events to date, outstanding
clinical usability outcome and space generating capability. HREC approval was granted for the
Tutelix pivotal trial towards the product clearance with the FDA.
01
Patient Impact
Score FY26
Tetratherix Limited 2026
Annual Report 2026
2026 Highlights
9
Tetratherix Limited 2026
Annual Report 2026
The FIH clinical trial for Tutelix product was initiated and all planned 15 patients completed their
treatment with no product related adverse event. The product administration was successfully
completed for all patients across two sites in Australia. The visibility of the product during its
deployment provides a safe and easy to use product for the clinicians while the mechanical
performance of the forming hydrogel and its “lift” strength formed an homogeneous space
anatomically between prostate and other tissues.
A. Tutelix First In Human Success
After injection (t=0) After Three Months After Six Months
Product displayed an outstanding structural stability at the injection site for 3 months. MRI results
displayed “water intake” at this time point which is a prerequisite for over time hydrolysis and
resorption of the injected structure. The uniformity of the structure and its stability for at least 3
months can provide solid basis to expand the application of the technology for pelvic cancer.
10
Tetratherix Limited 2026
Annual Report 2026
TetraDerm clinical trial progressed in two sites in Australia. The results from the unblinded cohort 1
showed strong indications of efficacy for the technology to reduce scar formation. No report of
inflammation, seroma formation and no report of hypertrophic scarring are all aligned with the
expected mode of action for TetraDerm.
B. TetraDerm Clinical Trial Progress
Operation 1 Week 6 Weeks
6 Months 12 Months
Cohort 2 recruitment
with 18 patients
completed and
significant progress
has been achieved in
cohort 3 that
involves up to 1.5 m
wounds after breast
augmentation, belt
lipectomy and other
major surgeries.
70
Oldest patient
treated in the trial
with VSS of <1 at
all time points
years of age
9
Relatively large
wounds with no
healing issues
observed
cm wound length
0
No reports of
seroma formation
in any of the
treated wounds
seroma formation
ZERO
No reports of
inflammation from 2
weeks onwards in
any of the patients
inflammation
11
First Revenues of $4.2m*
Reaching the commercial inflection point. Tetratherix is now a revenue generating business, having
made the transition from a research and development house to a commercial entity.
This first revenue is an annual licensing fee that gives a single partner access to our intellectual
property, and it establishes a model we can extend as further partners are added across the entire
platform. Supply of the Tetramatrix™ platform polymer will build on this base, adding a second
stream to our revenue-generating potential.
02
Tetratherix Limited 2026
Annual Report 2026
2026 Highlights
*The $4.2 million licence revenue is being recognised on a straight-line basis over the 12-month period from April 2026. Of
this, $0.9 million has been recognised in the FY26 P&L, with the remaining $3.3 million to be recognised in FY27.
$4.2m in revenues
from Tetramatrix™
commenced in
2026
12
Completed First FDA Submission
A significant regulatory milestone met. In 2026 Tetratherix completed its first full FDA dossiers,
covering the performance and safety testing for our dental and orthopaedic bone regeneration
products ahead of their initial market launch in the United States.
The submissions were completed on the back of multiple pre-submission meetings with the FDA
and draw on 27 internal reports, the full suite of ISO 10993 preclinical safety studies, and two large-
animal performance studies. Completing this work sets the regulatory flywheel in motion and
makes each future submission easier to prepare. It is a licence to hunt and the beginning of a longer
journey.
03
Tetratherix Limited 2026
Annual Report 2026
2026 Highlights
13
Tetratherix Limited 2026
Annual Report 2026
As a novel platform material, and to enable effective and efficient motion of our flywheel for our
current and future FDA submissions, we went above and beyond to confirm the safety of our
polymer platform per ISO10993. An independent review of data with a biological safety scientist
and a principal toxicologist in the US concluded that the platform is safe as a weight-of-evidence
from numerous In vivo studies demonstrated no evidence of irritation, sensitisation, systemic
toxicity, genotoxicity, pyrogenicity or carcinogenecity from the platform.
FDA submission Data Read out
Week 8 Week 12
0
10
20
30
40
50
Total
Bone
Volume
(mm
)
Control Tegenix Control Tegenix
3
The results from these clinically
relevant models confirmed that
Tegenix: (a) acts as an effective
carrier for any type of bone grafts
(animal or human-derived) to
enhance their usability and
handling; (b) supports natural
healing with no inflammatory/
foreign body reaction to Tegenix
and (c) provides a 3D matrix to
hold them in place to enable
cellular ingrowth and activation.
The impact was more evident
where adhesivity of Tegenix matrix
play an important role (for
example in upper jaw).
14
Tetratherix Limited 2026
Annual Report 2026
FDA submission Data Read out
Tegenix site Control site
The sites were integrated with the host tissue, and the Tegenix treated sites demonstrated the
product’s proposition, allowing bone ingrowth within the grafted site, leading to greater bone
volume.
TegenEOS allows effective delivery of autografts to the site for effective integration of the newly
formed bone with the host environment (turquoise blue area showed the original location of the defect).
TegenEOS
15
Production Readiness Underway
Federal Government support for Australian export. With the backing of a $3.3m IGP grant, we have
begun building a purpose-designed advanced manufacturing facility in Sydney that will lift our
production capability tenfold, with completion expected in late 2026.
The facility adds 3,000 sqm of production space to our campus and positions Tetratherix to be a
leader in innovation for Australian advanced manufacturing, exporting globally. Capacity is being
brought online in stages to match global demand, and inventory is being built through the process to
supply both the Bone Regeneration and Precision Medicine franchises.
04
Tetratherix Limited 2026
Annual Report 2026
2026 Highlights
16
Precision Medicine Launch
05
Tetratherix Limited 2026
Annual Report 2026
2026 Highlights
Changing the way drugs are delivered, on the back of more than five years of mRNA delivery
research. Tetratherix has launched its Precision Medicine franchise, targeting the intersection of
consumer preventative medicine and metabolic health.
The franchise is built on years of complex pharmaceutical R&D and collaboration with big pharma on
mRNA delivery. The technology’s distinctive feature is the ability to hold active compounds in place
for controlled nasal delivery, avoiding injection entirely. Anchored by science, the technology’s
proposition has been validated by recent peer-reviewed publications covering the nasal delivery of
proteins, peptides and insulin.
New franchise
launched in the
fast growing drug
delivery market
17
Paving the Path with our Pipeline
06
Tetratherix Limited 2026
Annual Report 2026
2026 Highlights
Growing patient impact, anchored by science. Working closely with our development partners,
Tetratherix advanced the clinical safety and efficacy testing of its pipeline products across scar
prevention, urological spacing and cataract surgery.
In addition to our clinical trials for TetraDerm and Tutelix, that both reached significant clinical
milestones, we continued the development of our other pipeline products. BioOptix completed its
proof-of-concept preclinical studies, demonstrating that the product can maintain surgical space
and allow complete cataract surgery with no spike in eye pressure. We published our results in
multiple peer-reviewed journal articles on novel utility of our polymer platform for tissue healing and
precision medicine.
The Tetramatrix™
platform
continues to grow
18
A histological assessment of a pipeline Tissue Healing application in an animal model from UPenn (USA)
Tetratherix Limited 2026
Annual Report 2026
CEO FY26 Letter
Dear Shareholders,
Healthcare is moving in one direction: faster, cheaper, and further from the operating theatre than most legacy medical
technology companies are prepared to admit. In the United States, more than 80% of surgical procedures are now
performed outside a hospital inpatient bed. Ambulatory surgery centres, a $45.6 billion market today, are forecast to
grow past $55 billion in the US within five years, and regulators keep widening what can be done within them: CMS added
37 procedures to the approved ambulatory service centre (ASC) list in 2024 and another 21 in 2025, and by next year an
estimated third of all cardiac procedures in the US will be performed in an ASC rather than a hospital. Urology
intervention, orthopaedic surgery and general surgery are all following the same path. The economics behind the move
are straightforward. Procedures performed in an ambulatory setting typically cost 35% to 50% less than the same
procedure in a hospital outpatient department, a colonoscopy runs around 38% cheaper, a rotator cuff repair or knee
arthroscopy over 50% cheaper, and the US Medicare system alone saves more than $4 billion a year by moving care into
these settings. But to be clear – this shift applies to markets all around the world, with the EU, Australia and Asia catching
up to the US thematic.
Following, although we are pushing the progression to the clinic, Tetramatrix™ is not a platform built exclusively for
ambulatory settings, and that is deliberate. The Tetramatrix™ chemistry performs the same way inside a hospital theatre
as it does in an ASC, and our partners value that consistency: one specification that works wherever a case lands, rather
than a different product for outpatient sites and another for inpatient ones. Our role in this shift is to give partners a
material that lets them move with it at whatever pace their market does, hospital or ASC, and put them at the front of a
global trend rather than a cycle behind it. We spent much of FY26 in the rooms where this shift is being decided, meeting
the partners and clinicians who are actually reallocating volume between settings, and it confirmed the premise we built
this company around: a platform that reduces the footprint, time and cost of a procedure is exactly where the system is
heading, pushed by payers and regulators as much as by patients.
Tetramatrix was designed for that shift before the shift had a name most investors would recognise. Our patient impact
across our clinical programs built on the platform has grown by 58% in FY26, a number that will move quickly once our
regulatory position clears. Our bone regeneration products remain under active FDA review, with our 510(k) submissions
progressing through the process; our upcoming clearance is the gate that turns a research cohort into a commercial one,
and turns a product that has existed in a trial protocol into something a surgeon can reach for in an ASC or a hospital
theatre, wherever the case is booked.
There is a way to launch a medical technology properly, and it takes longer than the market tends to want. When a new
product reaches a physician’s hands for the first time, it is delivered into a person's body to manipulate biology – no mean
feat – and every launch we run follows the same discipline: a twelve to eighteen month seed program, run with a defined
and limited group of users, deliberately unhurried, built so we can watch exactly how the product performs, in which
patients, and under what training, before it goes anywhere near broad distribution. That seed period is what makes
everything that follows it trustworthy. A device used in the wrong patient, by a surgeon who has not been properly trained
on it, causes damage that compounds well past that single case, because trust in an entire category of care, once lost, is
close to impossible to rebuild. We take that risk seriously, on behalf of patients who have no way of knowing, from where
they sit, how carefully the company behind their treatment actually did this work. The seed program exists because being
slow, here, is the work itself, and we intend to keep doing it this way long after the market has stopped asking us to hurry.
This is exactly where twenty-plus years of experience commercialising medical technology globally earns its place at the
table, because we have seen how this goes right and how it goes wrong often enough to know which twelve to eighteen
months are worth spending before anyone touches broad distribution.
On the theme of deliberate patience, the approach to our orthopaedic partnership deserves some airtime, to further
explain the partner selection process which may be seen to be taking longer than some would like, despite this being a
targeted mission. Our first bone regeneration product – Tegenix - already moves through Henry Schein's team and will
soon launch into its distribution network in the US, which tells you the product performs and the surgeons assessing it are
excited. But, like this Henry Schein agreement’s structure exemplifies, a traditional distribution agreement is a different
thing from choosing who we co-develop the next generation of orthopaedic innovation with over the fifteen to twenty-
year horizon our licensing model is actually built around. We are running that process with the diligence a decision of that
length deserves: technical evaluation in both directions, clinical evidence exchanged rather than asserted, and enough
time in each other's labs and production lines to know whether the relationship holds up past a couple of quarters. We
would rather take our time and get the right partner than announce a name early because the market wants one in a
report. Shareholders should read the pace of this process as discipline, not delay.
19
Tetratherix Limited 2026
Annual Report 2026
CEO FY26 Letter
In FY26, we backed the science up with another genuine commercial result ahead of time. In March we signed our
inaugural drug delivery licence agreement with Superpower Health, a US consumer health g
Share your feedback
Discover